GSK and Hengrui Pharma collaborate on treatments for respiratory, immunology, inflammation, and oncology, including a PDE3/4 inhibitor for COPD. GSK gains an exclusive license for Hengrui's COPD ...
Arnuity™ Ellipta® now available in the US for once-daily treatment of asthma. Incruse® Ellipta® now available in the US for once-daily treatment for COPD. Arnuity ™ Ellipta (fluticasone furoate ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback